Trends in prostate specific antigen testing in Ireland: Lessons from a country without guidelines

Irish Journal of Medical Science

Volumn 179, Issue 1, 2010, Pages 43-49

  Drummond, F J ^a   Carsin, A E ^a   Sharp, L ^a   Comber, H ^a  

^a NATIONAL CANCER REGISTRY IRELAND   (Ireland)

Author keywords

Guidelines; Incidence; Mortality; Prostate cancer; Prostate specific antigen; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ANTIGEN DETECTION; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PROSTATE CANCER; PUBLIC HEALTH SERVICE;

AGE FACTORS; AGED; AGED, 80 AND OVER; HUMANS; INCIDENCE; IRELAND; MALE; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 77249158336     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11845-009-0376-7     Document Type: Article

References (43)

1. K McDavid J Lee JP Fulton J Tonita TD Thompson 2004 Prostate cancer incidence and mortality rates and trends in the United States and Canada Public Health Rep 119 2 174 186 15192905
2. K Mistry G Cable 2003 Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma J Am Board Fam Pract 16 2 95 101 10.3122/jabfm.16.2.95 10.3122/jabfm.16.2.95 12665174
3. N Pashayan J Powles C Brown SW Duffy 2006 Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia Br J Cancer 95 3 401 405 10.1038/sj.bjc.6603246 10.1038/sj.bjc.6603246 1:CAS:528:DC%2BD28Xnsl2iu7g%3D 16832417 (Pubitemid 44187607)
4. R Etzioni DF Penson JM Legler D di Tommaso R Boer PH Gann EJ Feuer 2002 Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 13 981 990 12096083
5. D Ilic D O'Connor S Green T Wilt 2006 Screening for prostate cancer Cochrane Database Syst Rev 3 CD00472
6. GL Andriole RL Grubb 3rd SS Buys D Chia TR Church MN Fouad EP Gelmann PA Kvale DJ Reding JL Weissfeld LA Yokochi ED Crawford B O'Brien JD Clapp JM Rathmell TL Riley RB Hayes BS Kramer G Izmirlian AB Miller PF Pinsky PC Prorok JK Gohagan CD Berg PLCO Project Team 2009 Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 13 1310 1319 10.1056/NEJMoa0810696 10.1056/NEJMoa0810696 1:CAS:528:DC%2BD1MXjs1ejsLk%3D 19297565
7. FH Schröder J Hugosson MJ Roobol TL Tammela S Ciatto V Nelen M Kwiatkowski M Lujan H Lilja M Zappa LJ Denis F Recker A Berenguer L Määttänen CH Bangma G Aus A Villers X Rebillard T van der Kwast BG Blijenberg SM Moss HJ de Koning A Auvinen ERSPC Investigators 2009 Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 13 1320 1328 10.1056/NEJMoa0810084 10.1056/NEJMoa0810084 19297566
8. J Ferlay P Autier M Boniol M Heanue M Colombet P Boyle 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 581 592 10.1093/annonc/mdl498 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D 17287242 (Pubitemid 46359643)
9. Comber H Trends in Irish cancer incidence 1994-2002 with projections to 2020. http://www.ncri.ie/pubs/pubfiles/proj-2020.pdf
10. A Strategy for Cancer Control in Ireland National Cancer Forum, 2006. http://www.dohc.ie/publications/
11. F Drummond L Sharp H Comber 2008 Major inter-laboratory variations in PSA testing practices: results from national surveys in Ireland in 2006 and 2007 IJMS Ir J Med Sci 177 4 317 323 10.1007/s11845-008-0216-1 10.1007/s11845-008- 0216-1 1:STN:280:DC%2BD1cjjsVOlsA%3D%3D
12. NCR National Cancer Registry (2001) Cancer in Ireland, 1994 to 1998: incidence, mortality, treatment and survival, report of the National Cancer Registry. Cork, Ireland
13. MJ Roobol DW Roobol FH Schröder 2005 Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? Urology 65 343 346 10.1016/j.urology.2004. 09.046 10.1016/j.urology.2004.09.046 15708050 (Pubitemid 40248025)
14. BE Sirovich LM Schwartz S Woloshin 2003 Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 289 1414 1420 10.1001/jama.289.11.1414 10.1001/jama.289.11.1414 12636464 (Pubitemid 37430309)
15. A Gavin P McCarron RJ Middleton G Savage D Catney D O'Reilly PF Keane LJ Murray 2004 Evidence of prostate cancer screening in a UK region BJU Int 93 730 734 10.1111/j.1464-410X.2003.04716.x 10.1111/j.1464-410X.2003.04716.x 1:STN:280:DC%2BD2c7ls1Oltg%3D%3D 15049981 (Pubitemid 38497019)
16. J Melia S Moss 2001 Survey of the rate of PSA testing in general practice Br J Cancer 85 5 656 657 10.1054/bjoc.2001.1962 10.1054/bjoc.2001.1962 1:STN:280:DC%2BD3MvovFygsA%3D%3D 11531246 (Pubitemid 32929459)
17. J Melia S Moss L John Contributors in the participating laboratories 2004 Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study BJU Int 94 51 56 10.1111/j.1464-4096.2004.04832.x 10.1111/j.1464-4096.2004.04832.x 15217430 (Pubitemid 38980308)
18. JM Legler EJ Feuer AL Potosky RM Merrill BS Kramer 1998 The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States Cancer Causes Control 9 519 527 10.1023/A:1008805718310 10.1023/A:1008805718310 1:STN:280:DyaK1M7jtFCitA%3D%3D 9934717 (Pubitemid 29026914)
19. AB Mariotto R Etzioni M Krapcho EJ Feuer 2007 Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey Cancer 109 1877 1886 10.1002/cncr.22607 10.1002/cncr.22607 17372918 (Pubitemid 46668554)
20. Drummond FJ, Sharp L, Carsin A-E, Comber H (2007) Use of prostate specific antigen testing and prostatic biopsy in prostate cancer detection: a national survey of Urologists and Radiologists. UCC Annual Research Day
21. K Ito T Yamamoto K Suzuki K Kurokawa H Yamanaka 2004 The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less J Urol 171 2 Pt 1 656 660 10.1097/01.ju.0000100109. 23348.6b 10.1097/01.ju.0000100109.23348.6b 14713780 (Pubitemid 38090450)
22. Drummond FJ, Sharp L, Carsin A-E, Comber H (2007) What happens to men with an initial PSA value less than 4 ng/ml. American Association of Clinical Oncology, Florida
23. D Connolly A Black A Gavin PF Keane LJ Murray 2008 Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation Cancer Epidemiol Biomark Prev 17 2 271 278 10.1158/1055-9965.EPI- 07-0515 10.1158/1055-9965.EPI-07-0515 1:CAS:528:DC%2BD1cXhslarur4%3D (Pubitemid 351272775)
24. G Aus JE Damber A Khatami H Lilja J Stranne J Hugosson 2005 Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study Arch Intern Med 165 16 1857 1861 10.1001/archinte.165.16.1857 10.1001/archinte.165.16.1857 16157829 (Pubitemid 41352080)
25. MJ Roobol A Grenabo FH Schröder J Hugosson 2007 Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam J Natl Cancer Inst 99 17 1296 1303 10.1093/jnci/djm101 10.1093/jnci/djm101 17728218 (Pubitemid 47398681)
26. MJ Roobol DW Roobol FH Schröder 2005 Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam) Urology 65 2 343 346 10.1016/j.urology.2004.09.046 10.1016/j.urology.2004.09.046 15708050 (Pubitemid 40248025)
27. TJ Wilt T Shamliyan B Taylor R MacDonald J Tacklind I Rutks, et al. 2008 Screening for prostate cancer: U.S. Preventive Services Task Force Ann Intern Med 149 192 199
28. FJ Drummond A-E Carsin L Sharp H Comber 2009 Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners BMC Fam Pract 10 3 10.1186/1471-2296-10-3 10.1186/1471-2296-10-3 19138385
29. T Imamura H Yasunaga 2008 Economic evaluation of prostate cancer screening with prostate-specific antigen Int J Urol 15 285 288 10.1111/j.1442-2042.2008.02013.x 10.1111/j.1442-2042.2008.02013.x 18380812
30. S Carlsson G Aus C Wessman J Hugosson 2007 Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA)-results from a prospective, population-based, randomised study Eur J Cancer 43 14 2109 2116 10.1016/j.ejca.2007.06.002 10.1016/j.ejca.2007.06.002 17643983 (Pubitemid 47380358)
31. UK National Screening Committee Prostate Cancer Risk Management. Programme 2001. http://www.cancerscreening.nhs.uk/prostate/index.html
32. RA Smith V Cokkinides HJ Eyre 2006 American Cancer Society guidelines for the early detection of cancer, 2006 CA Cancer J Clin 56 11 25 10.3322/canjclin.56.1.11 10.3322/canjclin.56.1.11 16449183
33. American Urological Association 2000 Prostate specific antigen (PSA) best practice policy Oncology (Williston Park) 14 267 272
34. U.S. Preventive Services Task Force 2008 Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement 2008 Ann Intern Med 149 185 191
35. DA Lawson EJ Simoes D Sharp T Murayi R Hagan RC Brownson J Wilkerson 1998 Prostate cancer screening-a physician survey in Missouri J Community Health 23 347 358 10.1023/A:1018745821888 10.1023/A:1018745821888 1:STN:280: DyaK1M%2FhtVantQ%3D%3D 9793832 (Pubitemid 28465348)
36. WP Moran SJ Cohen JS Preisser JL Wofford BJ Shelton MW McClatchey 2000 Factors influencing use of the prostate-specific antigen screening test in primary care Am J Manag Care 6 315 324 1:STN:280:DC%2BD3M%2FgsV2qtw%3D%3D 10977432
37. Action prostate cancer. http://www.cancer.ie/prostate/
38. Drummond FJ, Sharp L, Comber H (2008) PSA testing and the impact of national recommendations in general practice: a semi-qualitative study. http://www.ncri.org.uk/ncriconference/2008abstracts/abstracts/C105.htm
39. GA Colditz KM Emmons K Vishwanath JF Kerner 2008 Translating science to practice: community and academic perspectives J Public Health Manag Pract 14 144 149 18287920
40. JF Kerner 2008 Integrating research, practice, and policy: what we see depends on where we stand J Public Health Manag Pract 14 193 198 18287927
41. SM Collin RM Martin C Metcalfe D Gunnell PC Albertsen D Neal F Hamdy P Stephens JA Lane R Moore J Donovan 2008 Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study Lancet Oncol 9 445 452 10.1016/S1470-2045(08)70104-9 10.1016/S1470-2045(08)70104-9 18424233
42. Carsin A-E, Drummond FJ, Black A, van Leeuwen PJ, Murray LJ, Connolly D, Egevad L, Autier P, Comber H, Gavin A. PSA testing and prostatic biopsy: population-based study of impact on cancer incidence and mortality. (under review)
43. DH Brewster LA Fraser V Harris RJ Black 2000 Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int 85 463 472 10.1046/j.1464-410x.2000.00487.x 10.1046/j.1464-410x.2000.00487.x 1:STN:280:DC%2BD3c7lslSjtg%3D%3D 10691826 (Pubitemid 30142623)